Citius Oncology Total Current Liabilities 2022-2024 | CTOR

Citius Oncology total current liabilities from 2022 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.

Citius Oncology Total Current Liabilities 2022-2024 | CTOR

Citius Oncology total current liabilities from 2022 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$158.3B
Bristol Myers Squibb (BMY)$119.4B
Vertex Pharmaceuticals (VRTX)$116.1B
Gilead Sciences (GILD)$112.4B
CSL (CSLLY)$87.2B
Regeneron Pharmaceuticals (REGN)$81.1B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.6B
Alnylam Pharmaceuticals (ALNY)$31.6B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$23B
Illumina (ILMN)$22.2B
BeiGene (BGNE)$18.6B
Moderna (MRNA)$15.8B
Incyte (INCY)$13.8B
Genmab (GMAB)$13.7B
Insmed (INSM)$13.1B
BioMarin Pharmaceutical (BMRN)$12.2B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.1B
Intra-Cellular Therapies (ITCI)$9.1B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.9B